Withdrawal reactions after stopping hypnotics in patients with insomnia

CNS Drugs

Volumn 10, Issue 6, 1998, Pages 425-440

  Lader, Malcolm ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; FLURAZEPAM; HYPNOTIC AGENT; MELATONIN; NITRAZEPAM; TEMAZEPAM; TRIAZOLAM; ZOLPIDEM; ZOPICLONE;

ARTICLE; COMORBIDITY; DOSE RESPONSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; INSOMNIA; PRIORITY JOURNAL; REBOUND; RELAPSE; RISK BENEFIT ANALYSIS; WITHDRAWAL SYNDROME;

EID: 0032438356     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199810060-00004     Document Type: Article

References (113)

1. Lader M. Anxiety or depression during withdrawal of hypnotic treatments. J Psychosom Res 1994; 38 Suppl. 1: 113-23
2. Lader M, Lawson C. Sleep studies and rebound insomnia: methodological problems, laboratory findings, and clinical implications. Clin Neuropharmacol 1987; 10: 291-312
3. Nowell PD, Mazumdar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia. JAMA 1997; 278 (24): 2170-7
4. Robertson JR, Treasure W. Benzodiazepine abuse: nature and extent of the problem. Drugs 1996; 5 (2): 137-46
5. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: Pt I. Therapeutic considerations. Clin Pharmacokinet 1991; 21 (3): 165-77
6. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: Pt II. Therapeutic considerations. Clin Pharmacokinet 1991; 21 (4): 262-73
7. Herings RMC, Stricker BHC, de Boer A, et al. Benzodiazepines and the risk of falling leading to femur fractures: dosage more important than elimination half-life. Arch Intern Med 1995; 155: 1801-7
8. Task Force Report. Benzodiazepine. Dependence, toxicity and abuse. Washington, DC: American Psychiatric Association. 1990
9. Noble S, Langtry D, Lamb HM. Zopiclone: an update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 1998; 55: 2-29
10. Freeman H, Puech AJ, Roth T, editors. Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier, 1996
11. A receptor function is different from that of benzodiazepines. Naunyn Schmiedebergs Arch Pharmacol 1994; 350: 294-300
12. A/benzodiazepine receptor. Adv Biochem Psychopharmacol 1992; 47: 407-18
13. A receptor subtypes and the mechanism of action of zolpidem. In: Freeman H, Puech AJ, Roth T, editors. Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier, 1996: 21-31
14. Benavides J, Abadie P, Baron JC, et al. In vivo interaction of zolpidem with (benzodiazepine) site subtypes. In: Freeman H, Puech AJ, Roth T, editors. Zolpidem: an update of its pharmacological properties and therapeutic place in the management ot insomnia. Paris: Elsevier, 1996: 33-43
15. Sanger DJ, Morel E, Perrault G. Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem. Eur J Pharmacol 1996; 313: 35-42
16. Ford DE, Kamerow DB. Epidemiological study of sleep disturbances and psychiatric disorders. An opportunity for prevention. JAMA 1988; 262: 1479-84
17. Schramm E, Hohagen F, Käppler C. et al.Mental comorbidity of chronic insomnia in general practice attenders using DSM-III-R. Acta Psychiatr Scand 1991; 91: 10-7
18. Üstün TB, Privett M, Lecrubier Y, et al. Form, frequency and burden of sleep problems in general health care: a report from the WHO Collaborative Study on Psychological Problems in General Health Care. Eur Arch Psychiatry Clin Neurosci 1989; 193: 113-24
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987
20. Ohayon M. Epidemiological study on insomnia in the general population. Sleep 1996; 19: S7-S15
21. Geiselmann B, Linden M. Prescription and intake patterns in long-term and ultra-long-term benzodiazepine treatment in primary care practice. Pharmacopsychiatry 1991; 24: 55-61
22. Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997; 154: 1417-23
23. Quera-Salva MA, Orluc A, Goldenberg F, et al. Insomnia and use of hypnotics: study of a French population. Sleep 1991; 14: 386-91
24. Morgan K, Dallosso H, Ebrahim S, et al. Prevalence, frequency, and duration of hypnotic drug use among the elderly living at home. BMJ 1988; 296: 601-2
25. Soldatos CR, Dikeos DG. Efficacy and rebound of five hypnotics in the elderly: a critical review. In: Vellas B, Albarede JL, editors. Sleep disorders and insomnia in the elderly. Paris: Serdi, 1993: 209-21
26. Pouchout J, Lombrail P, Sitbon P, et al. Sedative and hypnotic withdrawal states in inpatients [letter]. Lancet 1991; 338: 1022
27. Kales A, Scharf MB, Kales JD. Rebound insomnia: a new clinical syndrome. Science 1978; 201: 1039-40
28. Kales A, Soldatos CR, Bixler EO, et al. Rebound insomnia and rebound anxiety: a review. Pharmacology 1983; 26: 121-37
29. Roehrs T, Vogel G, Roth R. Rebound insomnia: its determinants and significance. Am J Med 1990; 88 Suppl. 3A: 395-425
30. Schneider-Helmert D. Why low-dose benzodiazepine-dependent insomniacs can't escape their sleeping pills. Acta Psychiatr Scand 1988; 78: 706-11
31. Schneider-Helmert D. Benzodiazepine withdrawal and rebound insomnia [reply]. Acta Psychiatr Scand 1989; 80: 298
32. Pelissolo A, Bisserbe J-C. Dépendance aux benzodiazépines. Aspects cliniques et biologiques. L'Encéphale 1994; 20: 147-57
33. Lader M. Rebound insomnia and newer hypnotics. Psychopharmacology 1992; 108: 248-55
34. Angst J, Borbely A, Engel RR, et al. Report on the sixth consensus conference on the methodology of clinical trials with hypnotic drugs. Pharmacopsychiatrics 1998; 28: 2-7
35. Liljenberg B, Almqvist M, Broman JE, et al. The effects of chlormethiazole in EEG recorded sleep in normal elderly volunteers. Acta Psychiatr Scand 1986; 73 Suppl. 329: 34-9
36. Lucas RE, Montgomery WS. Glutethimide withdrawal syndrome -the ethics of supply and demand [case report]. Aust NZJ Med 1992; 22: 708
37. Gillin JC, Spinweber CL, Johnson LC. Rebound insomnia: a critical review. J Clin Psychopharmacol 1989; 9: 161-72
38. Kales A, Scharf MB, Bixler EO, et al. Dose-response studies of quazepam. Clin Pharmacol Ther 1981; 30: 194-200
39. Adam K, Adamson L, Brezinova V, et al. Nitrazepam: lastingly effective but trouble on withdrawal. BMJ 1976; 1: 1558-60
40. Oswald I, French C, Adam K, et al. Benzodiazepine hypnotics remain effective for 24 weeks. BMJ 1982; 284: 860-3
41. Scharf MB, Bixler EO, Kales A, et al. Long-term sleep laboratory evaluation of flunitrazepam. Pharmacology 1979; 19: 173-81
42. Kales A, Manfredi RL, Vgontzas N, et al. Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines. Clin Pharmacol Ther 1991; 49: 468-76
43. Drake J. Temazepam 'Planpak': a multicentre general practice trial in planned benzodiazepine hypnotic withdrawal. Curr Med Res Opin 1991; 12: 390-3
44. Drake J. Temazepam 'Planpak', a fixed-dose reduction regimen for withdrawing benzodiazepine hypnotics: results of a general practice survey. Curr Med Res Opin 1991; 12: 394-7
45. Kales A, Bixler EO, Soldatos CR, et al. Lorazepam: effects on sleep and withdrawal phenomena. Pharmacology 1986; 32: 121-30
46. Kales A, Bixler EO, Vela-Bueno A, et al. Alprazolam: effects on sleep and withdrawal phenomena. J Clin Pharmacol 1987; 27: 508-15
47. Oswald I, Adam K, Borrow S, et al. The effects of two hypnotics on sleep, subjective feelings and skilled performance. In: Pussouant O, Oswald I, editors. Pharmacology of the states of alertness. Oxford: Pergamon, 1979: 51-63
48. Mamelak M, Csima A, Price V. The effects of a single night's dosing with triazolam on sleep the following night. J Clin Pharmacol 1990; 30: 549-55
49. Langley MS, Clissold SP. Brotizolam: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic. Drugs 1988; 35: 104-122
50. Mamelak M, Csima A, Buck L, et al. A comparative study on , the effects of brotizolam and flurazepam on sleep and performance in the elderly. J Clin Psychopharmacol 1989; 9: 260-7
51. Merlotti L, Roehrs T, Zorick FJ, et al. Rebound insomnia: duration of use and individual differences. J Clin Psychopharmacol 1991; 11: 368-73
52. Pecknold J, Wilson R, LeMorvan P. Long term efficacy and withdrawal of zopiclone: a sleep laboratory study. Int Clin Psychopharmacol 1990; 5 Suppl. 2: 57-67
53. Fleming JAE, Bourgouin J, Hamilton P. A sleep laboratory evaluation of the long-term efficacy of zopiclone. Can J Psychiatry 1988; 33: 103-7
54. Dorian P, Sellers EM, Kaplan H. Evaluation of zopiclone physical dependence liability in normal volunteers. Pharmacology 1983; 27 Suppl. 2: 228-34
55. Lader M, Freka G. Subjective effects during administration and on discontinuation of zopiclone and temazepam in normal subjects. Pharmacopsychiatry 1987; 20: 67-71
56. Tiberge M, Calvet V, Khayi N, et al. Comparison des effets de la zopiclone et du triazolam sur le sommeil du sujet sain. Encéphale 1988; 14: 319-324
57. Fontaine R, Beaudry P, Le Morvan P, et al. Efficacy and rebound insomnia of zopiclone and triazolam. Psychopharmacology 1988; 96 Suppl.: 219
58. Fontaine R, Beaudry P, Le Morvan P, et al. Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety. Int Clin Psychopharmacol 1990; 5: 173-83
59. Fleming A, McClure DJ, Mayes C, et al. A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia. Int Clin Psychopharmacol 1990; 5 Suppl. 2: 29-37
60. Phillips R, Howarth BG. Comparison of zopiclone and flurazepam in depressed patients suffering from insomnia. Internal Report no. ZD 0173. Rhone-Poulenc Rorer, 1985
61. Dehlin O, Rundgren A, Borjesson L, et al. Zopiclone to geriatric patients: a parallel double-blind dose-response clinical trial of zopiclone as a hypnotic to geriatric patients - a study in a geriatric hospital. Int Pharmacopsychiat 1982; 27 Suppl. 2: 173-8
62. Elie R, Deschenes JP. Efficacy and tolerance of zopiclone in insomniac geriatric patients. Int Pharmacopsychiat 1982; 17 Suppl. 2: 179-87
63. Bergener M, Gola R, Hesse C. The influence of age-dependent pharmacokinetics on the pharmacodynamics of hypnotic drugs: comparison of two hypnotics with different half-lives. Int Psychogeriatr 1989; 1 (1): 17-29
64. Elie R, Frenay M, LeMorvan P, et al. Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs. Int Clin Psychopharmacol 1990; 5 Suppl. 2: 39-46
65. Mouret J, Ruel D, Maillard, F, et al. Zopiclone versus triazolam in insomniac geriatric patients: a specific increase in delta sleep with zopiclone. Int Clin Psychopharmacol 1990; 5 Suppl. 2: 47-55
66. Lader M. Zopiclone: is there any dependence and abuse potential? J Neurol 1997: 244 Suppl. 1: S18-S22
67. Chiffoleau A, Baudot S, Larousse C, et al. Zopiclone: what does happen after discontinuation of long-term treatment? Proceedings of I 3ème Journees Francaises de Pharmacovigilance; 1991 Oct 28-29; Nice
68. Lemoine P, Allain H, Janus C, et al. Gradual withdrawal of zopiclone (7.5mg) and zolpidem (10mg) in insomniacs treated for at least 3 months. Eur Psychiatry 1995; 10 Suppl. 3: 161S-5S
69. Roth T, Hartse KM, Saab PG, et al. The effects of flurazepam, lorazepam, and triazolam on sleep and memory. Psychopharmacology 1980; 70: 231-7
70. Billiard M, Besset A, Delustrac C, et al. Dose-response effects of zopiclone on night sleep, and on night-time and daytime functioning. Sleep 1987: 10 Suppl. 1: 27-34
71. Shapiro CM, MacFarlane JG, MacLean AW. Alleviating sleep-related discontinuance symptoms associated with benzodiazepine withdrawal: a new approach. J Psychosom Res 1993; 37 Suppl. 1: 55-7
72. Shapiro CM, Sherman D, Peck DF. Withdrawal from benzodiazepines by initially switching to zopiclone. Eur Psychiatry 1995; 10 Suppl. 3: 145s-51s
73. Inman W, Kubota K, Pearce, G, et al. Report no. 10. Zopiclone. Pharmacoepidemiol Drug Saf 1993; 2: 499-521
74. Alvarez MaD, Alvarez de la C, Navarro SMaJ. Zopiclona: estudio de postcomercialización en España. Psiquis 1994; 15: 17-24
75. Rhône-Poulenc Rorer. Zopiclone. Pharmacovigilance data, update of 28 Feb (1993)
76. Rhône-Poulenc Rorer. Zopiclone. Pharmacovigilance data, 1 Mar 1993 to 28 Feb 1994 (1994)
77. Jones IR, Sullivan G. Physical dependence on zopiclone: case reports. BMJ 1998; 316: 117
78. Bianchi M, Musch B. Zopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena. Int Clin Psychopharmacol 1990; 5 Suppl. 2: 139-45
79. Vogel G, Poirrier R. Studies of effects following discontinuation of zolpidem treatment. In: Freeman H, Puech AJ, Roth T, editors. Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier, 1996: 149-60
80. Blois R, Gaillard JM, Attali P, et al. Effect of zolpidem on sleep in healthy subjects: a placebo-controlled trial with polysomnographic recordings. Clin Ther 1993; 15: 797-809
81. Nobuhara K, Isotani T, Okajima Y, et al. On the effects of zolpidem on nocturnal sleep: a whole night polysomnographic study in normal subjects. Jpn J Neuropsychopharmacol 1992; 14: 137-44
82. Kryger MH, Steljes D, Pouliot Z, et al. Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem. Sleep 1991; 14: 399-407
83. Besset A, Tafti M, Villemin E, et al. Effects of zolpidem on the architecture and cyclical structure of sleep in poor sleepers. Drugs Exp Clin Res 1995; 21: 161-9
84. Hux G, Wichester T, McDannold M, et al. The effects of zolpidem 20mg on REM density [abstract]. Sleep Res 1990; 19: 62
85. Silvestri R, Ferrillo F, Murri L, et al. Rebound insomnia after abrupt discontinuation of hypnotic treatment: double-blind randomized comparison of zolpidem versus triazolam. Hum Psychopharmacol 1996; 11: 225-33
86. Monti JM, Monti D, Estévez F, et al. Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal. Int Clin Psychopharmacol 1996; 11: 255-63
87. Kurtz D, Baas V, Rumbach L. Effects of repeated administration of zolpidem 10mg on sleep and diurnal wakefulness in poor sleepers. In: Kurtz D, Monti JM, editors. Stilnox. Proceedings of the 1st Imidazopyridine Symposium. Chester: Adis International. 1991: 43-50
88. De Roeck JMJ. Cluydts RJG. A polysomnographic study of short-term treatment with zolpidem in chronic psychophysiological insomnia. In: Kurtz D, Monti JM, editors. Stilnox. Proceedings of the 1st Imidazopyridine Symposium. Chester: Adis International, 1991: 34-42
89. Hermann WM, Kubicki ST, Boden S, et al. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation. J Int Med Res 1993; 21: 306-22
90. Scharf MB, Roth T, Vogel GW, et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994; 55: 192-9
91. Monti JM, Attali P, Monti D, et al. Zolpidem and rebound insomnia - a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 1994; 17: 166-75
92. Ware JC, Walsh JK, Scharf MB, et al. Minimal rebound insomnia after treatment with 10mg zolpidem. Clin Neuropharmacol 1997; 20 (2): 116-25
93. Biondi F, Casadei gL. Results of a multicenter trial with the hypnotic zolpidem in 1152 insomniac patients. Curr Ther Res 1994; 55: 262-74
94. De Domenico P, Silvestri R, Di Perri R, et al. Terapia dell' insonnia in età geriatrica: studio clinico con zolpidem, ipnotico a struttura imidazopiridinica. Argomenti Neurol 1991; 1: 197-205
95. Lorizio A, Terzano MG, Parrino L, et al. Zolpidem: a double-blind comparison of the hypnotic activity and safety of a 10-mg versus 20-mg dose. Curr Ther Res 1990; 47: 889-98
96. Guazzelli M, Ciapparelli A, Balsamo EL, et al. Terapia dell'insonnia correlata con i disturbi depressivi. Studio in doppio cieco sugli effetti della somministrazione e della sospensione di zolpidem versus flunitrazepam in pazienti depressi insonni. Minerva Psichiatr 1993; 34: 193-203
97. Roger M, Attali P, Coquelin JP. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin Ther 1993; 15: 127-35
98. Cohn MA, Allard S, Macintyre J. The use of zolpidem in the treatment of elderly patients with chronic insomnia [abstract]. Neuropsychopharmacology 1994; 10 Suppl. 3 (Pt 2): 22S
99. Schlich D, L'Heritier C, Coquelin JP, et al. Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res 1991; 19: 271-9
100. Kummer J. Longterm treatment with Zolpidem (Bikalm) over a period of 180 days under polysomnographic control in elderly [abstract]. Nauuyn Schmiederberg's Arch Pharmacol 1995; 351 Suppl. 1: 9
101. Pringney D, Salliere D. Tolerability and safety of zolpidem. In: Freeman H, Puech AJ, Roth T, editors. Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier, 1996: 195-214
102. Cavallaro R, Regazzetti MG, Covelli G, et al. Tolerance and withdrawal with zolpidem [letter]. Lancet 1993; 342: 374-5
103. Gilbert GL, Staats PS. Seizure after withdrawal from supra-therapeutic doses of zolpidem tartrate, a selective Omega I benzodiazepine receptor agonist. J Pain Symptom Manage 1997; 14 (2): 118-20
104. Ravishankar A, Carnwath T. Zolpidem tolerance and dependence - two case reports. J Psychopharmacol 1998; 12: 103-4
105. Watsky E. Management of zolpidem withdrawal [case history]. J Clin Psychopharmacol 1996; 16: 459
106. Allain H, Rahola JG. Switching to zolpidem in patients habituated to long-term benzodiazepine use. In: Freeman H. Puech AJ, Roth T. editors. Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier, 196: 176-82
107. Paty J, Anastassiou E, Besset A, et al. Efficacité et tolérance de la substitution de benzondiazépines hypnotiques par le zolpidem. Étude ouverte en médecine genérale. Psychologic Medicale 1991; 23: 1521-5
108. Ciapparelli A, Colombo C, Cuccato G, et al. Passagio exabrupto a zolpidem, nuovo ipnotico imidazopiridinico, in pazienti insonni già in trattamento con ipnotici benzodiazepinici. Minerva Psichiatr 1993; 34: 29-38
109. Garfinkel D, Laudon M, Nof D, et al. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995; 346: 541-4
110. Dement WC, Mitler MM. It's time to wake up to the importance of sleep disorders. JAMA 1993; 269 (12): 1548-9
111. Leger D. The cost of sleep-related accidents: a report for the National Commission on Sleep Disorders Research. Sleep 1994; 17 (1): 84-93
112. World Psychiatric Association. Task Force on sedative hypnotics. Eur Psychiatry 1993; 8: 45-9
113. Lader M, editor. The medical management of insomnia in general practice. Royal Society of Medicine, 1992. Round Table Series: 28